Overview

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Status:
Completed

Trial end date:
2018-02-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to learn whether it is safe and effective to administer HKI-272 (neratinib) in combination with paclitaxel in patients with breast cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Puma Biotechnology, Inc.

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel